[go: up one dir, main page]

ES2170720A1 - Utilizacion conjunta del gen de la insulina y del gen de la glucoquinasa en el desarrollo de aproximaciones terapeuticas para la diabetes mellitus. - Google Patents

Utilizacion conjunta del gen de la insulina y del gen de la glucoquinasa en el desarrollo de aproximaciones terapeuticas para la diabetes mellitus.

Info

Publication number
ES2170720A1
ES2170720A1 ES200003056A ES200003056A ES2170720A1 ES 2170720 A1 ES2170720 A1 ES 2170720A1 ES 200003056 A ES200003056 A ES 200003056A ES 200003056 A ES200003056 A ES 200003056A ES 2170720 A1 ES2170720 A1 ES 2170720A1
Authority
ES
Spain
Prior art keywords
gene
glucokinase
development
diabetes mellitus
insulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES200003056A
Other languages
English (en)
Other versions
ES2170720B1 (es
Inventor
Tubert Fatima Bosch
Goya Pedro Otaegui
Pastor Efren Riu
Masferrer Tura Ferri
Monteys Alejandro Mas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitat Autonoma de Barcelona UAB
Original Assignee
Universitat Autonoma de Barcelona UAB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitat Autonoma de Barcelona UAB filed Critical Universitat Autonoma de Barcelona UAB
Priority to ES200003056A priority Critical patent/ES2170720B1/es
Priority to US10/451,091 priority patent/US20040055023A1/en
Priority to AU2002216125A priority patent/AU2002216125A1/en
Priority to EP01271144A priority patent/EP1360898A1/en
Priority to CA002432506A priority patent/CA2432506A1/en
Priority to PCT/ES2001/000493 priority patent/WO2002049423A1/es
Publication of ES2170720A1 publication Critical patent/ES2170720A1/es
Application granted granted Critical
Publication of ES2170720B1 publication Critical patent/ES2170720B1/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
    • C12Y207/01002—Glucokinase (2.7.1.2)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0325—Animal model for autoimmune diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Environmental Sciences (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Utilización conjunta del gen de la insulina y del gen de la glucoquinasa en el desarrollo de aproximaciones terapéuticas para la diabetes mellitus. La presente invención se refiere a un animal doble transgénico que expresa simultáneamente el gen o el cDNA (ADN complementario) de la insulina y el gen o el cDNA (ADN complementario) de la glucoquinasa dirigidos por un promotor o fusión de promotores que permiten expresar insulina y glucoquinasa en músculo y su utilización en el desarrollo de aproximaciones terapéuticas para la diabetes mellitus. La presente invención también se refiere a un vector o vectores de expresión que permite expresar conjuntamente dichos genes quiméricos en células musculares. Dichos vectores pueden ser un plásmido, un vector viral o un vector no viral.
ES200003056A 2000-12-20 2000-12-20 Utilizacion conjunta del gen de la insulina y del gen de la glucoquinasa en el desarrollo de aproximaciones terapeuticas para la diabetes mellitus. Expired - Fee Related ES2170720B1 (es)

Priority Applications (6)

Application Number Priority Date Filing Date Title
ES200003056A ES2170720B1 (es) 2000-12-20 2000-12-20 Utilizacion conjunta del gen de la insulina y del gen de la glucoquinasa en el desarrollo de aproximaciones terapeuticas para la diabetes mellitus.
US10/451,091 US20040055023A1 (en) 2000-12-20 2001-12-19 Joint utilization of the insulin gene and the glucokinase gene in the development of therapeutic approaches for diabetes mellitus
AU2002216125A AU2002216125A1 (en) 2000-12-20 2001-12-19 Joint utilization of the insulin gene and the glucokinase gene in the development of therapeutic approaches for diabetes mellitus
EP01271144A EP1360898A1 (en) 2000-12-20 2001-12-19 Joint utilization of the insulin gene and the glucokinase gene in the development of therapeutic approaches for diabetes mellitus
CA002432506A CA2432506A1 (en) 2000-12-20 2001-12-19 Joint utilization of the insulin gene and the glucokinase gene in the development of therapeutic approaches for diabetes mellitus
PCT/ES2001/000493 WO2002049423A1 (es) 2000-12-20 2001-12-19 Utilizacion conjunta del gen de la insulina y del gen de la glucoquinasa en el desarrollo de aproximaciones terapeuticas para la diabetes mellitus

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200003056A ES2170720B1 (es) 2000-12-20 2000-12-20 Utilizacion conjunta del gen de la insulina y del gen de la glucoquinasa en el desarrollo de aproximaciones terapeuticas para la diabetes mellitus.

Publications (2)

Publication Number Publication Date
ES2170720A1 true ES2170720A1 (es) 2002-08-01
ES2170720B1 ES2170720B1 (es) 2003-12-16

Family

ID=8496075

Family Applications (1)

Application Number Title Priority Date Filing Date
ES200003056A Expired - Fee Related ES2170720B1 (es) 2000-12-20 2000-12-20 Utilizacion conjunta del gen de la insulina y del gen de la glucoquinasa en el desarrollo de aproximaciones terapeuticas para la diabetes mellitus.

Country Status (6)

Country Link
US (1) US20040055023A1 (es)
EP (1) EP1360898A1 (es)
AU (1) AU2002216125A1 (es)
CA (1) CA2432506A1 (es)
ES (1) ES2170720B1 (es)
WO (1) WO2002049423A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
US8034822B2 (en) 2006-03-08 2011-10-11 Takeda San Diego, Inc. Glucokinase activators
JP5386350B2 (ja) 2006-05-31 2014-01-15 タケダ カリフォルニア インコーポレイテッド グルコキナーゼ活性剤としての、インダゾールおよびイソインドール誘導体
US8163779B2 (en) 2006-12-20 2012-04-24 Takeda San Diego, Inc. Glucokinase activators
WO2008116107A2 (en) 2007-03-21 2008-09-25 Takeda San Diego, Inc. Piperazine derivatives as glucokinase activators
EP2388317B1 (en) * 2009-01-07 2017-08-30 Hangzhou Yiyuan Biotechnology Co. Ltd. A gene encoding a human glucokinase mutant, and uses thereof in the treatment or prevention of disease
WO2012007458A1 (en) 2010-07-12 2012-01-19 Universidad Autónoma De Barcelona Gene therapy composition for use in diabetes treatment
WO2013117776A1 (es) * 2012-02-08 2013-08-15 Fundación Pública Andaluza Progreso Y Salud Enzimas glucocinasas con actividad aumentada y su uso en el tratamiento y/o prevención de la diabetes mellitus
EP2692868A1 (en) 2012-08-02 2014-02-05 Universitat Autònoma De Barcelona Adeno-associated viral (AAV) vectors useful for transducing adipose tissue
CA2960912A1 (en) 2014-09-16 2016-03-24 Universitat Autonoma De Barcelona Adeno-associated viral vectors for the gene therapy of metabolic diseases
EP3242945B1 (en) 2015-01-07 2021-09-01 Universitat Autònoma de Barcelona Single-vector gene construct comprising insulin and glucokinase genes
US11319354B2 (en) 2019-07-10 2022-05-03 Masonic Medical Research Laboratory VGLL4 with UCP-1 cis-regulatory element and method of use thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995000644A1 (en) * 1993-06-28 1995-01-05 Board Of Regents, The University Of Texas System Vectors for genetically engineered cells that produce insulin in response to glucose
WO1995025169A1 (es) * 1994-03-14 1995-09-21 Universitat Autonoma De Barcelona Gen quimerico que utiliza el gen o cdna de la insulina, en especial para terapia genica de la diabetes
WO1997017994A1 (es) * 1995-11-16 1997-05-22 Universidad Autonoma De Barcelona Tratamiento de la diabetes con un gen de glucoquinasa
WO2000031267A1 (en) * 1998-11-20 2000-06-02 The Autonomous University Of Barcelona Insulin production by engineered muscle cells

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995000644A1 (en) * 1993-06-28 1995-01-05 Board Of Regents, The University Of Texas System Vectors for genetically engineered cells that produce insulin in response to glucose
WO1995025169A1 (es) * 1994-03-14 1995-09-21 Universitat Autonoma De Barcelona Gen quimerico que utiliza el gen o cdna de la insulina, en especial para terapia genica de la diabetes
WO1997017994A1 (es) * 1995-11-16 1997-05-22 Universidad Autonoma De Barcelona Tratamiento de la diabetes con un gen de glucoquinasa
WO2000031267A1 (en) * 1998-11-20 2000-06-02 The Autonomous University Of Barcelona Insulin production by engineered muscle cells

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LEE et al. "Myosin Light Chain-2 Luciferase Transgenic Mice Reveal Distinct Regulatory Programs for Cardiac and Skeletal Muscle-specific Expression of a Single Contractile Protein Gene". 1992. J. Biol. Chem., Vol. 267, paginas 15875-15885. *

Also Published As

Publication number Publication date
AU2002216125A1 (en) 2002-07-01
CA2432506A1 (en) 2002-06-27
US20040055023A1 (en) 2004-03-18
WO2002049423A1 (es) 2002-06-27
ES2170720B1 (es) 2003-12-16
EP1360898A1 (en) 2003-11-12

Similar Documents

Publication Publication Date Title
ES2170720A1 (es) Utilizacion conjunta del gen de la insulina y del gen de la glucoquinasa en el desarrollo de aproximaciones terapeuticas para la diabetes mellitus.
MX2022015079A (es) Variantes de hsd17b13 y usos de las mismas.
HRP20200647T1 (hr) Genski vektor
NO20064953L (no) Human GLP-1 mimetilegemer, sammensetninger, fremgangsmater og anvendelser
AR079958A2 (es) Sistema hospedador-vector para la propagacion del plasmido coie1 sin anti-biotico
WO2006096815A3 (en) NOVEL hTMC PROMOTER AND VECTORS FOR THE TUMOR-SELECTIVE AND HIGH-EFFICIENT EXPRESSION OF CANCER THERAPEUTIC GENES
DOP2022000122A (es) Analogos de incretina y sus usos
NO20090780L (no) Human Glp-1 mimetistoff, sammensetninger, fremgangsmater og anvendelser
WO2007014363A3 (en) Vectors for inducible expression of hairpin rna and use thereof
CY1115658T1 (el) Νεος βακιλοϊικος φορεας
PH12022550676A1 (en) Cells with sustained transgene expression
SG158902A1 (en) Nucleic acid constructs
AU2003239823A8 (en) Optimization of transgene expression in mammalian cells
DK564789A (da) Fremgangsmaade til ekspression af et eukaryot gen
Li et al. Identification of functionally important amino acid residues in the mitochondria targeting sequence of hepatitis B virus X protein
BR0209551A (pt) Promotor de gene especìfico de folha de café
Kong et al. Efficacy of lentivirus-mediated and MUC1 antibody-targeted VP22-TK/GCV suicide gene therapy for ovarian cancer.
US9926359B2 (en) Optogenetic inhibition of overactive neuronal activity
Beikmohammadi et al. Generation of insulin‐producing hepatocyte‐like cells from human Wharton's jelly mesenchymal stem cells as an alternative source of islet cells
ES2156769B1 (es) Gen quimerico que permite expresar el gen o el cdna del factor de crecimiento similar a la insulina de tipo i (igf-i) en pancreas y su utilizacion para la terapia genica de la diabetes mellitus.
ES2156788B1 (es) Genes quimericos que utilizan el cdna en orientacion antisentido del transportador de glucosa-2 (glut2) y animales transgenicos no humanos que expresan dichos genes quimericos para su utilizacion en el estudio de la diabetes mellitus y en el desarrollo de aproximaciones terapeuti
Düzgüneş Suicide gene therapy
WO2009053104A3 (en) Viral vector system, a composition comprising the viral vector system and its use
Annoni Strategies for tolerance induction to gene therapy derived products
UA88601C2 (ru) Промотор il-18bp, его получение и применение

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20020801

Kind code of ref document: A1

Effective date: 20020801

FG2A Definitive protection

Ref document number: 2170720B1

Country of ref document: ES

FD2A Announcement of lapse in spain

Effective date: 20210326